Drug intelligence / Profile preview

GnRH antagonist + letrozole

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral, Subcutaneous

Overview

A combination therapy used in assisted reproductive technology that pairs a gonadotropin-releasing hormone (GnRH) antagonist with letrozole, an aromatase inhibitor. The GnRH antagonist prevents premature ovulation by blocking GnRH receptors in the pituitary gland, inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Letrozole reduces estrogen production by inhibiting the conversion of androgens to estrogens. This combination is primarily used in fertility treatments for patients with poor ovarian response or at risk of ovarian hyperstimulation syndrome.

Targets

GnRHR (Gonadotropin-releasing hormone receptor)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on GnRH antagonist + letrozole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GnRH antagonist + letrozole.

Explore the full profile